Blackxray Tech

In April 2025, 999 Family Office participated in the investment process of Black X-Ray Tech, contributing in an intermediary and supporting role to a £10 million Seed financing.

The transaction was structured through a convertible note.

Black X-Ray Tech operates in the field of information technology and software development, delivering advanced solutions and consultancy services to support digital transformation initiatives.

This investment represents a significant step in the company’s development, reinforcing its capacity to scale operations and accelerate innovation. We are pleased to have contributed to the successful execution of this transaction.

Malhar Limited

In September 2025, 999 Family Office supported the fundraising of Malhar Tech, acting in an intermediary capacity in connection with a £15 million Pre-Seed financing.

The round was structured through a convertible note.

Malhar Tech operates at the intersection of information technology consulting and technical analysis, delivering advanced solutions and expertise to support complex digital and engineering challenges.

This transaction represents a significant milestone at an early stage of development, providing the company with the resources to accelerate its growth, strengthen its technical foundation, and execute on its strategic roadmap. We are pleased to have contributed to the successful completion of this financing.

Dental Labor

In December 2024, 999 Family Office contributed to the capital raise of Dental Labor Zanini Stefano, acting in a supporting and intermediary role in connection with a £7.2 million Series B financing.

The investment was completed through an equity subscription.

Dental Labor Zanini Stefano operates as a specialized dental laboratory, focusing on the manufacturing of medical-grade dental products and providing high-quality services within the healthcare sector.

This transaction represents a key stage in strengthening the company’s financial position, enabling further growth and continued advancement of its capabilities. We are pleased to have supported the successful completion of this financing.

Derwydd

In January 2026, 999 Family Office had the pleasure of acting as an intermediary for the fundraising of Derwydd, successfully facilitating a £3.7 million raise through a convertible note and Seed round.

This fundraising milestone represents a significant step forward for Derwydd, and we are proud to support their growth and vision.

Oberland Biotech

In March 2026, 999 Family Office supported the capital raise of Oberland Biotech in an intermediary capacity, contributing to the successful completion of a CHF 2.5 million financing structured through a convertible note alongside a Seed round.

Oberland Biotech is dedicated to advancing next-generation solutions in food and biotech, combining cutting-edge research, fermentation processes, and ingredient innovation to address global nutrition and sustainability challenges.

This financing marks an important stage in the company’s development, and we are pleased to have played a role in enabling its continued expansion and strategic ambitions.

Contact Us

For any questions, feel free to contact us here.